Back grey_arrow_rt.gif
 
Archived NATAP Articles from January 2002
 
null.gif
 
 
  1. ACT II; GAY AIDS ACTIVIST AND LIVER TRANSPLANT RECIPIENT TURNS ATTENTION TO RAISING AWARENESS OF NEED FOR ORGAN DONATION CHRISTOPHER SNOWBECK, POST-GAZETTE STAFF WRITER
    (01/31/02)

    2.  
  2. Immunology Overview - The importance of immunology Written for NATAP by Michael Norton, PA-C, Boriken Health Clinic, NYC - ICAAC Chicago, Ill. -
    (01/30/02)

    3.  
  3. HIV Robs Brain Power, Study Shows Miami Herald Stephen Smith
    (01/29/02)

    4.  
  4. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen
    (01/28/02)

    5.  
  5. Liver toxicity caused by nevirapine
    (01/28/02)

    6.  
  6. Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides
    (01/28/02)

    7.  
  7. Effect of Highly Active Antiretroviral Therapy on the Natural History of Anal Squamous Intraepithelial Lesions and Anal Human Papilloma virus Infection
    (01/24/02)

    8.  
  8. Can HIV-1-Contaminated Syringes Be Disinfected?
    (01/24/02)

    9.  
  9. Hepatitis C Report from AASLD: HIV/coinfection; new HCV drugs Written for NATAP by Andrew Talal, MD, Cornell-NY Hospital, GI and Hepatology Clinic
    (AASLD) Dallas, Texas
    (01/23/02)

    10.  
  10. FOCUS Study: 24-week interim analysis - ICAAC Chicago, Ill. -
    (01/17/02)

    11.  
  11. NEW AIDS CASES INCREASES
    (01/17/02)

    12.  
  12. LETTER FROM SCHERING PLOUGH: wait-list for PegIntron
    (01/17/02)

    13.  
  13. Update on Kaletra Resistance
    (01/17/02)

    14.  
  14. Pancreatitis in HIV - ICAAC Chicago, Ill. -
    (01/14/02)

    15.  
  15. Overview of Pharmacokinetic Properties of Pegasys
    (01/14/02)

    16.  
  16. How Does Interferon Work in Your Body
    (01/14/02)

    17.  
  17. Abacavir Resistance - ICAAC Chicago, Ill. -
    (01/14/02)

    18.  
  18. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin
    (01/14/02)

    19.  
  19. Bone Abnormalities at ICAAC: Osteoporosis, Osteonecrosis Written for NATAP by Michael Norton, PA-C, Boriken Health Clinic, NYC - ICAAC Chicago, Ill. -
    (01/10/02)

    20.  
  20. Selected Recent Developments in HIV Treatment and Research, from Recent Conferences:
    (01/10/02)

    21.  
  21. Hepatitis C Protease Inhibitors
    (01/09/02)

    22.  
  22. Isolated anti-HBc in chronic hepatitis C predicts a poor response to interferon treatment.
    (01/09/02)

    23.  
  23. NATAP REPORT OF HEPATITIS ABSTRACTS PRESENTED AT 52ND ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES Written for NATAP by Andrew Talal, MD, Cornell-Ny Hospital, NYC
    (AASLD) Dallas, Texas
    (01/07/02)

    24.  
  24. Hepatitis Report from ICAAC Nancy Shulman, MD, Stanford University - ICAAC Chicago, Ill. -
    (01/07/02)

    25.  
  25. Amprenavir "908" prodrug once & twice a day with Efavirenz. - ICAAC Chicago, Ill. -
    (01/07/02)

    26.  
  26. HEPATITIS ABSTRACTS PRESENTED AT 41ST ANNUAL INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPEUTICS Written by Andrew Talal, MD, Cornell-NY Hospital, NYC - ICAAC Chicago, Ill. -
    (01/04/02)

    27.  
  27. HIV/AIDS Programs Receive Funding Increases House and Senate Pass FY 2002 Labor-HHS- Education Appropriations Bill
    (01/04/02)

    28.  
  28. Selected review of HIV resistance presented at the 41st ICAAC Andrew R. Zolopa, MD Stanford University - ICAAC Chicago, Ill. -
    (01/04/02)

    29.  
  29. Entry Inhibitors Written by: Michael Norton, PA, Boriken Family Health Clinic
    (01/02/02)

    30.  
  30. How Low Does Viral Load Have To Be? - ICAAC Chicago, Ill. -
    (01/02/02)

    31.  
  31. Therapy Interruptions in HIV Written for NATAP by Michael Norton, PA, Boriken Family Health Clinic, NYC Editorial contribution by Jules Levin
    (01/02/02)

    32.  
  32. DDI EC and Food and Timing of Dosing - ICAAC Chicago, Ill. -a>
    (01/02/02)

    33.  
  33. TRIZAL: a randomized comparative study of switch to Trixivir compared to HAART in patients successfully treated with HAART
    (01/02/02)

    34.  
  34. Pharmacogenetics of Antiretrovirals
    (01/02/02)

    35.  
  35. Therapeutic Vaccinations in HIV Written by Michael Norton, PA, Boriken Family Health Clinic, NYC
    (01/02/02)

    36.  
  36. Structural normalization of the lymphoid tissue asymptomatic HIV-infected patients after 48 weeks potent antiretroviral therapy
    (01/02/02)

    37.  
  37. 40% HCV Prevalence in HIV Clinic in SF 
    (AASLD) Dallas, Texas
    (01/02/02)

    38.  
  38. Toxicities in HIV/HCV Coinfected Treated with Peg-Intron + RBV 
    (AASLD) Dallas, Texas
    (01/02/02)

    39.  
  39. TREATMENT OF HEPATITIS C CIRRHOSIS USING PEGYLATED INTERFERON: MONEY WELL SPENT?    
    (AASLD) Dallas, Texas
    (01/02/02)

    40.